Table 2.
Stem cell source, GVHD prophylaxis, and conditioning regimens
| Haplo, n (%) | MUD 10/10, n (%) | p value | |
|---|---|---|---|
| Stem cell source | |||
| BM | 129 (52) | 167 (6) | < 10−4 |
| PBSC | 121 (48) | 2422 (94) | |
| Missing | 0 | 0 | |
| GVHD prophylaxis | |||
| Csa based | 4 (2) | 426 (17) | < 10−4 |
| Csa + Mtx | 9 (4) | 656 (26) | |
| Csa + Mmf ± others | 12 (5) | 1123 (44) | |
| CSA + MMF ± MTX | 16 (7) | 29 (1) | |
| Tacro alone | 1 (0) | 20 (1) | |
| Mmf + Tacro/Mmf + Siro | 38 (16) | 185 (7) | |
| Mtx + Tacro | 0 (0) | 44 (2) | |
| Pt-Cy based | 156 (65) | 22 (1) | |
| Others | 14 (1) | 84 (1) | |
| In vivo TCD | |||
| No | 181 (74) | 648 (25) | < 10−4 |
| Yes | 63 (26) | 1915 (75) | |
| Missing | 6 | 26 | |
| Conditioning regimens | |||
| MAC | 66 (27) | 591 (23) | 0.238 |
| Bu-Cy/BuFlu | 7 | 253 | |
| TBF | 31 | 8 | |
| Flu-Mel | 7 | 81 | |
| TBI based | 4 | 61 | |
| Other | 17 | 188 | |
| RIC | 182 (73) | 1948 (77) | |
| Bu-Flu | 10 | 635 | |
| TBF | 55 | 19 | |
| Flu-Mel | 9 | 414 | |
| TBI based | 55 | 457 | |
| Other | 53 | 423 | |
Abbrevations: Haplo, haploidentical; MUD, matched unrelated donor; BM, bone marrow; PBSC, peripheral blood stem cell; GVHD, graft versus host disease; CSA, cyclosporine; MTX, methotrexate; MMF, mycophenolate; TACRO, tacrolimus; SIRO, sirolimus; PTCY, post-transplant cyclophosphamide; TCD, T-cell depletion; MAC, myeloablative conditioning; BU, busulphan, CY, cyclophosphamide; FLU, fludarabine; TBF, thiotepa busulphan fludarabine; MEL, melphalan; TREO, treosulphan; FLAMSA, fludarabine, amsacrine, and cytarabine; TBI, total body irradiation; RIC, reduced intensity conditioning